Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | PABPC1 | P11940 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13263619 | 0.91 | MEN1 (0.68) | MEN1KMT2AKDM4EMAPTLMNA | |
| SCHEMBL13298957 | 0.89 | MEN1 (0.64) | MEN1KMT2AKDM4EMAPTLMNA | |
| SCHEMBL19151059 | 0.88 | KMT2A (0.75) | MEN1KMT2AKDM4EMAPTLMNA | |
| SCHEMBL13233328 | 0.85 | KMT2A (0.68) | MEN1KMT2AKDM4EMAPTLMNA | |
| SCHEMBL8788394 | 0.85 | KMT2A (0.76) | MEN1KMT2AKDM4EMAPTLMNA | |
| SCHEMBL23222382 | 0.84 | KMT2A (0.66) | MEN1KMT2AKDM4EMAPTLMNA | |
| SCHEMBL19110996 | 0.84 | KMT2A (0.66) | MEN1KMT2AKDM4EMAPTLMNA | |
| SCHEMBL10509419 | 0.83 | KMT2A (1.00) | MEN1KMT2AKDM4EMAPTLMNA | |
| SCHEMBL6846377 | 0.83 | KMT2A (0.73) | MEN1KMT2AKDM4EMAPTLMNA | |
| SCHEMBL5648499 | 0.83 | KMT2A (0.68) | MEN1KMT2AKDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230183184-A1 | 3-(Carboxyethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183184-A1 | 3-(Carboxyethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| EP-3652157-B1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2021-05-05 | — | — | EP | disclosed |
| EP-3722283-A1 | 3-(CARBOXYETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2020-10-14 | — | — | EP | disclosed |
| EP-3402783-B1 | 3-(CARBOXYETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2020-03-04 | — | — | EP | disclosed |
| WO-2019012037-A1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | Grünenthal GmbH (DE) | 2019-01-17 | — | — | WO | disclosed |
| WO-2017121646-A1 | 3-(CARBOXYETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-07-20 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | MEN1 2863/4885KMT2A 4375/4885KDM4E 4699/4885 |
| US-20230183184-A1 | 3-(Carboxyethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, PKD2 | MEN1 2986/4885KMT2A 2284/4885KDM4E 1357/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | MEN1 4080/4885KMT2A 3544/4885KDM4E 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.